ADA2026: BGE-102, a Novel NLRP3 Inhibitor, Demonstrated Robust Anti-Inflammatory Activity in a Phase 1 Study in Healthy Volunteers and Participants with Obesity

Bioage Labs Inc. published this content on June 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 09, 2026 at 00:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]